Remove CMS Remove Heart Transplant Remove Quality of Life
article thumbnail

BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

DAIC

CMS has reviewed the CardiAMP Heart Failure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage. Treated patients also had reduced major adverse cardiac events and greatly improved quality of life. “We said Peter Altman , PhD.,

CMS 111